Saturday, August 2, 2025 8/2/2025

SCORE2 Comparative Trial (SCT)

Award Number: U10EY023529
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/30/2013
PERIOD OF PERFORMANCE END DATE: 03/31/2020

Group Awards By:

View Award Description

SCORE2 Comparative Trial (SCT) - DESCRIPTION (provided by applicant): This comparative effectiveness research proposal (Studies of Comparative Treatments for Retinal Vein Occlusion 2 [SC0RE2] Study) aims to support alternative treatment protocols for decreased vision due to macular edema secondary to central retinal vein occlusion (CRVO) based on results of recent randomized trials. This proposed study called the "SCORE2 Comparative Trial" (SCT) will determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema due to RVO. The non-inferiority margin will be set at an Early Treatment Diabetic Retinopathy Study visual acuity letter score of 5. The SCT will also provide insight into treatment regimens after the initial 6 months to determine if the frequency of intravitreal injections can be reduced in eyes that have responded well to treatment (which would represent a more cost-effective treatment regimen, with fewer risks to patients of injection-related adverse events and a lesser logistical treatment burden for patients and providers), and the impact of alternative treatment strategies (intravitreal dexamethasone) in eyes that have not responded well to initial treatment with anti-VEGF therapy. So, in addition to the primary aim of test for non-inferiority of bevacizumab to aflibercept in visual acuity outcome at Month 6 for eyes, secondary aims will investigate different dosing strategies after Month 6. In addition, secondary analyses will examine retinal thickening and other retinal outcomes based on SD-OCT and wide field fluorescein angiograms (within a subset of sites). The SCT will also add to our knowledge of the safety profile of these anti-vascular endothelial growth factor (anti-VEGF) medications. We propose to enroll 360 CRVO patients over a 24-month period, and follow for 13-months. This application is for The EMMES Corporation to serve as the Data Coordinating Center (DCC) for the SCT, with our primary focus to provide data management, statistical, and operational support over 5 years of support.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	EMMES COMPANY, LLC, THE	401 N WASHINGTON ST STE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	5	9/28/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2018	EMMES COMPANY, LLC, THE	401 N WASHINGTON ST STE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	5	5/13/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $1,059,710 )
2018	2018	EMMES CORPORATION, THE	401 N WASHINGTON ST STE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	5	3/28/2018	NON-COMPETING CONTINUATION	$1,059,710
														Subtotal = $1,059,710

Issue Date FY: 2017 ( Subtotal = $1,150,820 )
2017	2017	EMMES CORPORATION, THE	401 N WASHINGTON ST STE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	002	4	3/29/2017	NON-COMPETING CONTINUATION	$1,150,820
2017	2016	EMMES CORPORATION, THE	401 N WASHINGTON ST STE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	001	3	2/3/2017	EXTENSION WITH OR WITHOUT FUNDS	$42,516
2017	2015	EMMES CORPORATION, THE	401 N WASHINGTON ST STE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	2	2/3/2017	NON-COMPETING CONTINUATION	-$42,516
														Subtotal = $1,150,820

Issue Date FY: 2016 ( Subtotal = $1,518,590 )
2016	2016	EMMES CORPORATION	401 N WASHINGTON, SUITE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	3	3/23/2016	EXTENSION WITH OR WITHOUT FUNDS	$1,518,590
														Subtotal = $1,518,590

Issue Date FY: 2015 ( Subtotal = $1,583,822 )
2015	2015	EMMES CORPORATION	401 N WASHINGTON, SUITE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	001	1	2/3/2015	SUPPLEMENT FOR EXPANSION	$316,762
2015	2015	EMMES CORPORATION	401 N WASHINGTON, SUITE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	002	2	4/17/2015	NON-COMPETING CONTINUATION	$1,267,060
2015	2013	EMMES CORPORATION	401 N WASHINGTON, SUITE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	1	1/8/2015	NEW	$0
														Subtotal = $1,583,822

Issue Date FY: 2014 ( Subtotal = $74,903 )
2014	2014	EMMES CORPORATION	401 N WASHINGTON, SUITE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	001	1	9/12/2014	SUPPLEMENT FOR EXPANSION	$74,903
2014	2013	EMMES CORPORATION	401 N WASHINGTON, SUITE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	1	9/5/2014	NEW	$0
														Subtotal = $74,903

Issue Date FY: 2013 ( Subtotal = $1,433,393 )
2013	2013	EMMES CORPORATION	401 N WASHINGTON, SUITE 700	ROCKVILLE	MD	20850	MONTGOMERY	USA	Vision Research	000	1	9/18/2013	NEW	$1,433,393
														Subtotal = $1,433,393

Grand Total All Awards = $6,821,238

Top

All Categories

About

Search

Reports

Data Submission

Award Information

SCORE2 Comparative Trial (SCT)

Award Number: U10EY023529

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/30/2013

PERIOD OF PERFORMANCE END DATE: 03/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer